APA (7th ed.) Citation

Ratka, Z., Gamian, A., & Woźniak, M. (2026). Limited Clinical Benefit of Immune Checkpoint Inhibition in Ovarian Cancer with Opportunities in Selected Subtypes. International Journal of Molecular Sciences, 27(11), 4923. https://doi.org/10.3390/ijms27114923

Chicago Style (17th ed.) Citation

Ratka, Zuzanna, Andrzej Gamian, and Marta Woźniak. "Limited Clinical Benefit of Immune Checkpoint Inhibition in Ovarian Cancer with Opportunities in Selected Subtypes." International Journal of Molecular Sciences 27, no. 11 (2026): 4923. https://doi.org/10.3390/ijms27114923.

MLA (9th ed.) Citation

Ratka, Zuzanna, et al. "Limited Clinical Benefit of Immune Checkpoint Inhibition in Ovarian Cancer with Opportunities in Selected Subtypes." International Journal of Molecular Sciences, vol. 27, no. 11, 2026, p. 4923, https://doi.org/10.3390/ijms27114923.